Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4892MR)

This product GTTS-WQ4892MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4892MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7321MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ7918MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ2995MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ15709MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ2403MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ10901MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ10326MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ1542MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW